CTLA4 and hepatocellular carcinoma: Tremelimumab (anti-CTLA-4) was given to 32 advanced-stage HCC patients in a different experiment at doses of 3.5 and 10 mg/kg once every 30 days for six treatments; participants completed RFA on day three.